Active/Enrolling:
PRIOH-1
- Principal Investigator: Gary Wang, MD, PhD
- https://www.aicuris.com/75n6/Pritelivir-AIC316-.htm
- In this study, immunocompromised patients with the herpes simplex virus (HSV) have ulcers that are usually very deep, extensive, and associated with severe pain that poses a risk for serious complications. The standard treatment of acyclovir or valacyclovir is no longer working against acyclovir-resistant (ACV-R) HSV infection that can occur in any immunocompromised patient. This study seeks to evaluate the efficacy and safety of pritelivir, an oral inhibitor of HSV replication, for treatment of ACV-R HSV infections in immunocompromised adults with the aim to offer alternative treatment.
- Contact: IDGMClinicalResearch@medicine.ufl.edu
“Enrollment for this clinical trial has closed; however, our site is participating in an expanded access program, which allows qualifying patients to obtain access to pritelivir in a compassionate-use setting.”